New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
07:46 EDTKPTIKaryopharm announces initiation of Selinexor Phase 2 study
Karyopharm Therapeutics announced the initiation of a Phase 2 trial of its novel, oral Selective Inhibitor of Nuclear Export compound Selinexor, or KPT-330, in patients with metastatic hormone-refractory prostate cancer. The study, referred to as the SHIP, or Selinexor in Hormone Refractory Indications in Prostate Cancer, study, is led by Drs. Christopher Logothetis and John Araujo of the M.D. Anderson Cancer Center at the University of Texas in Houston and is being funded in part by a grant from the Prostate Cancer Foundation.
News For KPTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 30, 2015
16:12 EDTKPTIKaryopharm to hold a conference call
Following the formal presentation at the 57th Annual Meeting of ASH, management provides an update for its lead drug candidate, Selinexor (KPT-330), including new clinical data on a conference call to be held on December 7 at 8:30 pm. Webcast Link
16:03 EDTKPTIKaryopharm to present clinical data update for Selinexor
Karyopharm Therapeutics announced the presentation of clinical data for its lead drug candidate, selinexor (KPT-330), a first-in-class, oral Selective Inhibitor of Nuclear Export / SINE compound, during a Karyopharm-sponsored event with webcast scheduled for Monday, December 7, 2015 from 8:30 - 9:30 p.m. ET, immediately following formal programming for the 57th American Society of Hematology Annual Meeting. The event, entitled "Broadening the Foundation for SINE-Based Therapy in Oncology: ASH 2015," will include presentations by selinexor clinical investigators and Karyopharm management describing new clinical data, including data related to selinexor's activity in combination with other active agents in multiple myeloma and acute myeloid leukemia, followed by a Q&A session.
07:47 EDTKPTILeerink positive on Alnylam, Juno, Karyopharm into ASH meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use